Inhibition of sodium-glucose cotransporter 2 prevents sorafenib-induced depression-like behaviors by preserving hippocampal-dependent long-term potentiation.
The sodium-glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin has been reported to exert significant neuroprotective effects on neurobehavioral deficits; however, its effects on chemotherapy-induced neuroplastic changes have not yet been investigated. The present study investigates the behavioral changes and hipp...